Collegium Pharma (COLL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
August 5, 2020 4:02 PM EDT Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020
Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020
Xtampza ® ER Net Revenue Increased 29% over the Prior Year Period
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported... More
